Recombinant Mouse CD30/TNFRSF8 protein (His Tag)

种属

Mouse

纯度

>90 %, SDS-PAGE

标签

His Tag

生物活性

未测试

Cat no : Eg1307

Print datasheet

Synonyms

CD30, CD30L receptor, Lymphocyte activation antigen CD30, Tnfrsf8, Tumor necrosis factor receptor superfamily member 8



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性 Not tested
来源 HEK293-derived Mouse CD30 protein Phe19-Thr281 (Accession# Q60846) with a His tag at the C-terminus.
基因ID 21941
蛋白编号 Q60846
预测分子量 28.7 kDa
SDS-PAGE 30-40 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

CD30, also known as TNFRSF8 or Ki-1, is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. It is composed of an extracellular domain with six cysteine-rich repeats, a transmembrane segment, and an intracellular domain. CD30 is expressed on a small subset of activated T and B lymphocytes, and a variety of lymphoid neoplasms, with the highest expression in classical Hodgkin's lymphoma and anaplastic large cell lymphoma. The CD30 ligand (CD30L or CD153) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. Signal transduction of CD30/CD30L utilizes signal transducers, TNFR-associated factors (TRAF1, 2, 3 and 5).

参考文献:

1. Dürkop H. et al. (1992) Cell. 68(3):421-7. 2. Horie R. et al. (1998) Semin Immunol. 10(6):457-70. 3. van der Weyden CA. et al. (2017) Blood Cancer J. 7(9):e603. 4. Gruss HJ. et al. (1996) Am J Pathol. 149(2):469-81.